THE US Food and Drug Administration has announced it has approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.
While Lucemyra may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days.
More information at fda.gov.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 18
